- Only Issused Pantent for PolIII based RNAi
-
Protected under US patents 7,294,504 and 7,422,896, Allele´s RNAi System was invented by Allele scientists in 2001. In addition to its proven high efficiency, accuracy, and low cost, it has several major advantages over other shRNA expression technologies:
- Supplied as pre-cut linear vector ready to ligate, with nearly zero self-ligation background.
- No restriction sites are used, leaving no alteration of the U6 promoter or additional bases to the shRNA, resulting in optimal RNAi.
- Three versions available: Vector, Retrovirus and Lentivirus, accompanied with a designed Validation Reporter System
|
- HiTiter™ Lentiviral Expression System
-
Allele Biotech provides RNAi screening services based on its patented shRNA technology because its uses have been widely tested in many cancer relevant systems. In most cases we recommend the use of Allele´s lentiviral vector for shRNA that is ready-to-ligate and can be packaged at very high titer in small cultures. For an cost-efficient custom project to succeed several obstacles must be overcome with optimal combinations of the most suitable technologies for each step
More about Lentiviral RNAi Platform 
- Design of RNAi targets
- High throughput cloning
- Viral particle production
- RNAi screening
|
- Efficient Virus Packaging System
-
Allele Biotech uses the most efficient packaging methods to prepare high titer retrovirus or lentivirus particles. Already provided under Allele Viral Packaging Services, these technologies are also available for RNAi screening projects through Allele’s RNAi Validation/Screening Services. Allele’s pLICO and pCHAC lentivirus and retrovirus systems have integrated the most advanced knowledge of using these viruses safely and effectively as gene or RNAi delivery vehicles, and been widely used by thousands of labs around the world. Choosing Allele’s systems maximize the chances of success of RNAi screening projects.
Read More
|
- Fluorescent Protein Reporters
-
One of the main advantages that Allele Biotech provides to its RNAi customers is the availability of some of the very best fluorescent proteins (FP) as reporters. For instance, a surrogate reporter with target transcript and FP fusion can be created for quick analysis of RNAi effects, while lentiviral shRNA vectors can have another FP for transduction tracking and normalization. Currently Allele Biotech has the brightest teal/cyan FP mTFP1, green fluorescent protein mWasabi, yellow and red FPs from Amphioxus, and a soon to be disclosed photoconvertible FP. A license for use of these FPs can be obtained separately or incorporated with a CRO RNAi project.
RNAi Validation Reporter System
|
- RNAi Screening Using Linear DNA Template in Cell Arrays
-
Pol III promoter-driven expression of shRNA or siRNA strands can be achieved by creating an expression cassette on a PCR product such as Allele’s LineSilence. The linear DNA molecule can be linked through PCR primers to peptides that on one end immobilize the DNA molecule on the surface of an array, and on the other end lead to efficient cell transduction. This technology was invented by Allele Biotech. A US patent has been allowed in 2009 and it is now offered to customers for low cost and high-throughput RNAi screening in cultured cells.
|
